Project Grant R43CA285081
- Federal Project Grant Award Summary The National Cancer Institute awarded Am Operating LLC a Project Grant of $1.116M (awarded August 1, 2025; completion July 31, 2027) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop a standardized visualization, labeling, and tracking system for documenting skin cancer anatomic locations. The project delivers a technological platform that creates reproducible, standardized descriptions of skin cancer biopsy sites using...
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has awarded a $693,156 Project Grant (CFDA 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health) to the Dana-Farber Cancer Institute, Inc. (DFCI) to develop artificial intelligence (AI) algorithms for predicting prognosis and optimizing treatment selection for cutaneous squamous cell carcinoma (CSCC), a highly prevalent form of skin cancer. The project aims to train and validate AI...
- Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...
- This National Science Foundation Project Grant of $495,000 will support the development of biopsy-free, label-free three-dimensional virtual histology of intact skin through March 2025. Funded under the Engineering program (CFDA 47.041), the award to the University of California, Los Angeles aims to advance a machine learning-based technique to transform 3D skin images into virtually stained images that can facilitate accurate and rapid diagnosis of skin lesions without biopsy. Specifically, the...
- This federal Cooperative Agreement award, issued by the Department of the Interior's Interior Business Center under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384), supports the development of a novel imaging technology called "VISION" that enables real-time, high-resolution intraoperative detection of microscopic residual cancer cells during surgical procedures. The $5,160,920 award to the Regents of the University of California, San Francisco aims to...
- Federal Project Grant Award Summary Navigation Sciences Inc. received a $225,229 Project Grant award on September 19, 2025, from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop EndonaviSci, an advanced navigation software system designed to improve lung cancer surgical outcomes. The software will address critical clinical challenges in performing segmentectomy—a lung-preserving surgical procedure—by enabling accurate localization...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $704,028 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2026, through May 31, 2031. This five-year award supports a digitally-enabled randomized controlled trial comparing topical chemotherapy treatments for actinic keratoses (AKs), precancerous skin lesions that can progress to cutaneous squamous cell carcinoma (CSCC), the second...
- Radiosight LLC was awarded a $256,000 Small Business Technology Transfer (STTR) Phase I Project Grant by the National Science Foundation on May 1, 2021 to develop a point-of-care skin cancer imaging device. The award is being carried out under the NSF's Technology, Innovation, and Partnerships program (CFDA 47.084) and will support Radiosight's efforts to advance science and engineering research leading to breakthrough technologies. Specifically, the funding will allow Radiosight to work towards...
- Federal Grant Award Summary Illuminant Surgical Inc. received a $1,107,943 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on September 12, 2025, with a completion date of August 31, 2027. This Phase II effort focuses on the continued development and validation of Skylight, a mixed-reality navigation platform designed to improve the accuracy and safety of image-guided biopsy procedures. The platform employs advanced...
- Federal Project Grant Award Summary Award Details: The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded Brigham and Women's Hospital a $711,696 Project Grant effective July 1, 2026, through June 30, 2031, to modernize and rearchitect 3D Slicer, a free, open-source software platform for advanced medical image analysis. The grant supports an academic-industrial partnership focused on modularizing 3D Slicer's core architecture to...
DEVELOPMENT OF A NOVEL VISUALIZATION, LABELING, COMMUNICATION AND TRACKING ENGINE FOR HUMAN ANATOMY. - THE KEY TO TRACKING, COLLATING, AND COMMUNICATING SKIN CANCER DATA IS STANDARDIZATION, ENHANCED PRECISION, AND CATEGORIZATION OF ANATOMIC DESCRIPTIONS. IMPRECISE AND NON-STANDARDIZED LABELING OF ANATOMIC SITES FOR SKIN CANCER BIOPSIES CREATES CHALLENGES IN COMMUNICATING AND IDENTIFYING THE SKIN CANCER LOCATION AT THE TIME OF TREATMENT. DIAGNOSTIC BIOPSIES OFTEN REMOVE THE VISIBLE CANCER CELLS, AND SINCE SKIN CANCER MOST COMMONLY ARISES ON SUN- OR RADIATION-DAMAGED SKIN WITH NUMEROUS SURROUNDING OR CONTIGUOUS DISCOLORATIONS, LESIONS, AND SCARS, THE BIOPSY SITE CAN BE DIFFICULT TO FIND. FURTHERMORE, PHOTOS ARE NOT ALWAYS TAKEN AT TIME OF BIOPSY OR ARE NOT READILY AVAILABLE AT TIME OF SURGERY, AND MOST ELECTRONIC HEALTH RECORD (EHR) SYSTEMS RELY ON FREE-TEXT LABELING OF ANATOMIC SITES. THIS PROJECT AIMS TO CREATE METHODS TO DOCUMENT REPRODUCIBLE AND STANDARDIZED ANATOMIC SITE DESCRIPTIONS OF SKIN CANCER LOCATIONS, TO VISUALIZE SKIN CANCER LOCATIONS, AND TO ATTACH DATA RELATED TO SKIN CANCERS AT EACH AFFECTED ANATOMIC SITE. THE ANATOMIC SITE DESCRIPTIONS ARE ALSO ENHANCED WITH STANDARDIZED DIRECTIONAL MODIFIERS FOR INCREASED ACCURACY AND PRECISION, THEREBY CREATING A LINGUISTIC GLOBAL POSITION SYSTEM (GPS) FOR THE HUMAN BODY. THE PROJECT INVOLVES A SIMPLIFIED PROCESS TO ATTACH SKIN CANCER DIAGNOSES AND DIAGNOSTIC CODES TO STANDARDIZED ANATOMIC SITES WITH ENHANCED DESCRIPTIONS AND VISUALIZATIONS ACROSS THE SKIN SURFACE TOPOGRAPHY. PRECISE AND STANDARDIZED ANATOMIC LABELING WITH CORRESPONDING VISUALIZATIONS WILL FACILITATE COMMUNICATION BETWEEN CLINICS, INCREASE CLINICAL ACCURACY AND EFFICIENCY, AND ENHANCE PATIENT SAFETY AND UNDERSTANDING BY REDUCING THE RISK OF WRONG-SITE SURGERY FOR SKIN CANCER. THE PROJECT ALSO INTEGRATES FUNCTIONALITY TO SECURELY SEND FILES INCLUDING HIGH RESOLUTION, COLOR SKIN CANCER PHOTOS AND CORRESPONDING ANATOMIC MAP VISUALIZATIONS LINKED TO STANDARDIZED ANATOMY DESCRIPTIONS THROUGH EMAIL, THUS MITIGATING THE NEED TO COMMUNICATE PHOTOS AND RECORDS OVER POOR-QUALITY FAX METHODS OR POSTAL MAIL, WHILE SIMULTANEOUSLY MAINTAINING COMPLIANCE WITH REGULATORY STATUTES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 11/25/24 | ||
| Not listed | $386.9k | 9/15/23 |